Full Press Release Details
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “Perspectives on Progress”, this report communicates the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two key reporting frameworks: the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB), now part of the IFRS Sustainability Alliance.
Olivier Loeillot, President and Chief Executive Officer at Repligen, said, “At Repligen, we take a pragmatic approach to advancing our sustainability-related ambitions. To us, continuous improvement is sustainability and sustainability is business resilience.”
Dianne Heiler, Vice President of Sustainability & ESG and Global Head of Packaging Engineering at Repligen, said, “As world events continue to shape the conversation, the team at Repligen remains focused and committed to sustainability. Why? Because we know that it makes good sense and creates business value. This publication also serves as Repligen Corporation’s 2024 Communication on Progress in fulfillment of our annual commitment to the United Nations Global Compact (UNGC).”
Below are just a few of the 2024 Corporate Sustainability Report highlights across environmental, social and governance topics. Report data is through year end 2024 unless otherwise noted.
Advancing Impacts: Report Highlights
About Repligen CorporationRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are“inspiring advances in bioprocessing”for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information, please visitwww.repligen.com, and follow us onLinkedIn.
Forward Looking StatementsThis press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.